Evidence map›Paper›PMID 14713109›Full record

ArticleClinical & experimental metastasis2003

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.

Lesley J Murray, Tinya J Abrams, Kelly R Long, Theresa J Ngai, Lisa M Olson, Weiru Hong, Paul K Keast, Jacqueline A Brassard, Anne Marie O'Farrell, Julie M Cherrington and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00673816 (Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome), which is not on this map. Cited by 115 papers.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00673816 phase1 / phase2terminatednot on this mapstarted 2008, after this paper: background citation

Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome

TypeinterventionalSponsorNational Eye Institute (NEI)Ran2008 to 2011Enrolled2ConditionsVon Hippel-Lindau SyndromeArmsSunitinib Malate
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 304 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008
    Trial
  17. Trial
  18. Review
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Lesley J MurraySUGEN, Inc. South San Francisco, California, USA. drlesleymurray@yahoo.com
Tinya J Abrams
Kelly R Long
Theresa J Ngai
Lisa M Olson
Weiru Hong
Paul K Keast
Jacqueline A Brassard
Anne Marie O'Farrell
Julie M Cherrington
Nancy K Pryer
VistaGen Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to investigate inhibitory effects of the receptor tyrosine kinase (RTK) inhibitor SU11248 against CSF-1R and osteoclast (OC) formation. We developed an in vivo model of breast cancer metastasis to evaluate efficacy of SU11248 against tumor growth and tumor-induced osteolysis in bone. The in vitro effects of SU11248 on CSF-1R phosphorylation, OC formation and function were evaluated. Effects on 435/HAL-Luc tumor growth in bone were monitored by in vivo bioluminescence imaging (BLI), and inhibition of osteolysis was evaluated by measurement of serum pyridinoline (PYD) concentration and histology. Phosphorylation of the receptor for M-CSF (CSF-1R) expressed by NIH3T3 cells was inhibited by SU11248 with an IC50 of 50-100 nM, consistent with CSF-1R belonging to the class III split kinase domain RTK family. The early M-CSF-dependent phase of in vitro murine OC development and function were inhibited by SU11248 at 10-100 nM. In vivo inhibition of osteolysis was confirmed by significant lowering of serum PYD levels following SU11248 treatment of tumor-bearing mice (P = 0.047). Using BLI, SU11248 treatment at 40 mg/kg/day for 21 days showed 64% inhibition of tumor growth in bone (P = 0.006), and at 80 mg/kg/day showed 89% inhibition (P = 0.001). Collectively, these data suggest that SU11248 may be an effective and tolerated therapy to inhibit growth of breast cancer bone metastases, with the additional advantage of inhibiting tumor-associated osteolysis.

Indexed as

OsteolysisAnimalsBone NeoplasmsBreast NeoplasmsCell AdhesionIndolesMiceMice, NudeNeoplasm TransplantationOsteoclastsPhosphorylationPyrrolesReceptor, Macrophage Colony-Stimulating FactorReceptor Protein-Tyrosine KinasesSunitinibTumor Cells, CulturedIndolesPyrrolesReceptor, Macrophage Colony-Stimulating FactorReceptor Protein-Tyrosine KinasesSunitinib

Identifiers

PMID14713109
OpenAlexW1976689062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.